Appeal 2007-2516
Application 10/302,553
40°C, a bulk density of less than about 0.5 g/cm3, and a mass
median aerodynamic diameter from about 0.5 - 10 µm.
16. A method for providing lung surfactant therapy to a patient
in need thereof, the method comprising:
decreasing an oxygen index of a patient by at least 20%
by administering a dry powder composition by inhalation to the
respiratory tract of the patient, the dry powder composition
comprising lung surfactant and particles, the particles
comprising phospholipid and calcium, and the particles having
a gel to liquid crystal phase transition temperature greater than
about 40°C, a bulk density of less than about 0.5 g/cm3, and a
mass median aerodynamic diameter from about 0.5 - 10 µm.
19. A method for providing lung surfactant therapy to a patient
in need thereof, the method comprising:
decreasing an oxygen index of a patient by at least 40%
by administering a dry powder composition as a dry powder
aerosol by inhalation to the respiratory tract of a patient in a
plurality of inhalations over a 30 minute period, the dry powder
composition comprising lung surfactant and particles, the
particles comprising phospholipid and calcium, the particles
having a gel to liquid crystal phase transition temperature
greater than about 40°C, a bulk density of less than about 0.5
g/cm3, and a mass median aerodynamic diameter from about
0.5 - 10 µm.
FINDINGS OF FACT
Hafner ‘970
1. Hafner ‘970 teaches that adult respiratory distress syndrome (ARDS) can
be treated with lung surfactant (Hafner ‘970, col. 1, ll. 20-24; col. 2, ll. 9-
10).
2. Lung surfactant “has surface-active properties and reduces the surface
tension in the alveolar region of the lungs” (Hafner ‘970, col. 3, ll. 10-12).
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: September 9, 2013